Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Cost-Saving,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA1 + APR) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Singapore.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Singapore.,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN),Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA1 + APR),SE
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Cost-Saving,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) VERSUS Standard doublet dexamethasone + first generation serotonin-3 receptor antagonists (DEX + 5HT3RA1) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN),Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Standard doublet dexamethasone + first generation serotonin-3 receptor antagonists (DEX + 5HT3RA1),SE
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Cost-Saving,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) VERSUS Standard doublet dexamethasone + first generation serotonin-3 receptor antagonists (DEX + 5HT3RA1) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN),Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Standard doublet dexamethasone + first generation serotonin-3 receptor antagonists (DEX + 5HT3RA1),SE
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Cost-Saving,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) VERSUS Standard doublet dexamethasone + first generation serotonin-3 receptor antagonists (DEX + 5HT3RA1) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN),Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Standard doublet dexamethasone + first generation serotonin-3 receptor antagonists (DEX + 5HT3RA1),SE
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Dominated,Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.,Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA,Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN),NW
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Dominated,Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.,Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA,Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN),NW
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Dominated,Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.,Dexamethasone + first generation serotonin-3 receptor antagonists + aprepitant triplet (DEX + 5HT3RA,Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN),NW
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Dominated,Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.,Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA,Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN),NW
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Dominated,Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.,Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA,Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN),NW
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Dominated,Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Singapore.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Singapore.,Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA,Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN),NW
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Dominated,Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.,Dexamethasone + second generation serotonin-3 receptor antagonists+ aprepitant triplet (DEX + 5HT3RA,Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN),NW
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Dominated,Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple VERSUS Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.,Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple,Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN),NW
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Dominated,Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple VERSUS Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.,Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple,Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN),NW
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Dominated,Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple VERSUS Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Singapore.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Singapore.,Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple,Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN),NW
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Dominated,Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple VERSUS Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.,Dexamethasone+second generation serotonin-3 receptor antagonists + aprepitant + olanzapine quadruple,Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Dexamethasone+ second generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA2 + OLN),NW
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Dominated,Doublet dexamethasone + second generation serotonin-3 receptor antagonists (DEX + 5HT3RA2) VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Indonesia.,Doublet dexamethasone + second generation serotonin-3 receptor antagonists (DEX + 5HT3RA2),Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN),NW
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Dominated,Doublet dexamethasone + second generation serotonin-3 receptor antagonists (DEX + 5HT3RA2) VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Malaysia.,Doublet dexamethasone + second generation serotonin-3 receptor antagonists (DEX + 5HT3RA2),Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN),NW
2018-01-26483,2018,Chanthawong 2018 Support Care Cancer,Dominated,Doublet dexamethasone + second generation serotonin-3 receptor antagonists (DEX + 5HT3RA2) VERSUS Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN) IN Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.,30112718,Specific disease- Patients with highly emetogenic chemotherapy; Age- Adult; Gender- Both; Country- Thailand.,Doublet dexamethasone + second generation serotonin-3 receptor antagonists (DEX + 5HT3RA2),Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.,Dexamethasone + first generation serotonin-3 receptor antagonists + olanzapine (DEX + 5HT3RA1 + OLN),NW
2017-01-25475,2017,Afiatin 2017 PLoS One,13000,"Peritoneal dialysis-first policy VERSUS Supportive care (fluid restriction, high-dose diuretics, hypertensive drugs, calcium bicarbonate, ferrous sulfate, and blood transfusion) IN Specific disease- End-stage renal disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Indonesia; Other- Patients who cannot afford dialysis or kidney transplantation.",28545094,"Specific disease- End-stage renal disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Indonesia; Other- Patients who cannot afford dialysis or kidney transplantation.",Peritoneal dialysis-first policy,Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia.,"Supportive care (fluid restriction, high-dose diuretics, hypertensive drugs, calcium bicarbonate, ferrous sulfate, and blood transfusion)",NE
2017-01-25475,2017,Afiatin 2017 PLoS One,14000,"Hemodialysis-first policy VERSUS Supportive care (fluid restriction, high-dose diuretics, hypertensive drugs, calcium bicarbonate, ferrous sulfate, and blood transfusion) IN Specific disease- End-stage renal disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Indonesia; Other- Patients who cannot afford dialysis or kidney transplantation.",28545094,"Specific disease- End-stage renal disease; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Indonesia; Other- Patients who cannot afford dialysis or kidney transplantation.",Hemodialysis-first policy,Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia.,"Supportive care (fluid restriction, high-dose diuretics, hypertensive drugs, calcium bicarbonate, ferrous sulfate, and blood transfusion)",NE
1 2 3 4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
